NeuClone's advantage in biosimilar drug production
Many global generic pharmaceutical companies are developing biosimilars. Prominent obstacles to entry into this market include the sizeable investments in time and expertise associated with cell line development. NeuClone has a number of distinct advantages to offer drug manufacturers who are investing in biotech drug development programs, including:
Biosimilar drug portfolio
NeuClone is applying its suite of technologies to generate a portfolio of cell lines expressing biosimilars. NeuClone has a number of NeuCHO™ cell lines producing biosimilar monoclonal antibodies (mAbs) available for licensing. In addition to biosimilar mAbs, NeuClone is developing cell lines expressing other complex biosimilar APIs requiring post translational modification.
Our business is to make an almost exact copy of off-patent biologic APIs - from primary sequence to finished product according the guidelines established by the European Medicines Agency’s on Similar Biological Medicinal Products.
Contact us to discuss your particular requirements.